ScreenerHero

OVID Ovid Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · ovidrx.com
2.340USD-0.85%Mkt Cap: 457.00M $P/E: —

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The co…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap457.00M USD
Enterprise Value358.35M USD
Revenue (TTM)1.58M USD
Gross Profit1.58M USD
Net Income (TTM)-17.41M USD
Revenue/Share0.01 USD
Last Price2.340 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.12
PEG—
EV/EBITDA-6.18
EV/Revenue226.38
P/S292.39
P/B2.09
EPS (TTM)-0.22
EPS (Forward)-0.39
52W Range
1.18060% of range3.105
52W High3.105 USD
52W Low1.180 USD
Profitability
Gross Margin100.00%
Oper. Margin-2100.68%
EBITDA Margin0.00%
Profit Margin-240.13%
ROE-13.33%
ROA-11.54%
Growth
Revenue Growth-88.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.33M USD
CapEx (TTM)—
FCF Margin-2092.31%
FCF Yield-7.25%
Net Debt-104.50M USD
Net Debt/EBITDA1.80
Balance Sheet
Debt/Equity0.10
Current Ratio12.39
Quick Ratio11.74
Book Value/Sh1.14 USD
Cash/Share0.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.024 USD
Upside (mean)+157.4%
Target Range4.000 USD – 9.000 USD
4.000+157.4% to mean9.000
# Analysts10
Ownership
Shares Out.195.30M
Float163.39M
Insiders6.72%
Institutions80.42%
Short Interest
Short Ratio14.8d
Short % Float12.40%
Short % Out.10.83%
Shares Short21.15M
Short (prev mo.)21.64M
Technical
SMA 502.639 (-11.3%)
SMA 2002.300 (+1.7%)
Beta0.23
S&P 52W Chg16.45%
Avg Vol (30d)1.70M
Avg Vol (10d)1.78M
Technical Indicators
RSI (14)36.8
MACD-0.0843
MACD Signal-0.0575
MACD Hist.-0.0268
BB Upper2.850 USD
BB Middle2.542 USD
BB Lower2.234 USD
BB Width24.23%
ATR (14)0.1371 USD
Vol Ratio (20d)0.94x